Treatment of hepatitis C virus infection in intravenous drug users

Acta Neuropsychiatrica

Volumn 18, Issue 5, 2006, Pages 183-192

  Cowan, Matthew L ^a   Maxwell, James D ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Hepatitis C virus; Intravenous drug use; Therapy

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; HEPATITIS C VACCINE; METHADONE; NUCLEOSIDE DERIVATIVE; OPIATE; PARACETAMOL; REBETRON;

ANEMIA; ANXIETY DISORDER; ARTHRALGIA; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DOSE RESPONSE; DRUG BINDING; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HISTORY OF MEDICINE; HUMAN; INFLUENZA; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER TRANSPLANTATION; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL EXPERT; MEDICAL PRACTICE; MEDICAL SPECIALIST; MYALGIA; OPIATE ADDICTION; PRACTICE GUIDELINE; PSYCHOSIS; REHABILITATION CARE; REVIEW; RIGOR; RISK FACTOR; SELF ESTEEM; VIRUS REPLICATION;

EID: 33750444619     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2006.00136.x     Document Type: Review

References (99)

1. CHOO QL, KUO G, WEINER AJ, OVERBY LR, BRADLEY DW, HOUGHTON M. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
2. WORLD HEALTH ORGANISATION. Hepatitis C: global prevalence - update. Wkly Epidemiol Rec 1997;72:341-344.
3. ALTER MJ, KRUSZON-MORAN D, NAINAN OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
4. BOOTH JCL, O'GRADY J, NEUBERGER J. Clinical guidelines on the management of hepatitis C. Gut 2001;49(Suppl I): i1-i21.
5. ALTER MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62s-65s.
6. RAMSAY ME, BALOGUN MA, HARRIS HE. Epidemiology and health burden of hepatitis C in the UK. In: BASSENDINE M, FOSTER G, MILES A, eds. The effective management of hepatitis C infection. London: Aesculapius, 2003: 15-29.
7. JUDD A, HICKMAN M, JONES S et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. Br Med J 2005;330:24-25.
8. SIMMONDS P, ALBERTI A, ALTER HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-1324.
9. RAI R, WILSON LE, ASTEMBORSKI J, ANANAIA F et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002;35:1247-1255.
10. RYDER SD. The natural history of hepatitis C infection. In: BASSENDINE M, FOSTER G, MILES A, eds. The effective management of hepatitis C infection. London: Aesculapius, 2003:3-14.
11. KANAI K, KAKO M, OKAMOTO H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
12. TSUBOTA A, CHAYAMA K, IKEDA K et al. Factors predictive of response to interferon-therapy in hepatitis C virus infection. Hepatology 1994;19:1088-1094.
13. ALBERTI A, MORSILA G, CHEMELLO L et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-698.
14. RYDER SD. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451-455.
15. SOBESKY R, MATHURIN P, CHARLOTTE F et al. Modelling the effect of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378-386.
16. MCCAUGHAN GW, GEORGE J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004;53:318-321.
17. WRIGHT M, GOLDIN R, FABRE AM et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis c virus infection. Gut 2003;52:574-579.
18. BATALLER R, NORTH KE, BRENNER DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-502.
19. FATTOVICH G, GIUSTINA G, DEGOS F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;1112:436-472.
20. TSUKUMA H, HIYAMA T, TANAKA S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Eng J Med 1993;328:1797-1801.
21. FOSTER GR, GOLDIN RD, THOMAS HC. Chronic hepatitis C virus infection causes a significant reduction in the quality of life in the absence of cirrhosis. Hepatology 1998;27:209-212.
22. WESSELY S, PARIENTE C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002;32:1-10.
23. FORTON DM, THOMAS HC, MURPHY CA et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-439.
24. FORTON DM, ALLSOP JM, MAIN J, FOSTER GR, THOMAS HC, TAYLOR-ROBINSON SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38-39.
25. KRAMER L, BAUER E, FUNK G et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002;37:349-354.
26. RADKOWSKI M, WILKINSON J, NOWICKI M et al. Search for hepatitis C virus negative strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002;76:600-608.
27. HADZIYANNIS S. Non hepatic manifestations of chronic HCV infection. J Viral Hepat 1997;4:1-17.
28. STRADER DB, WRIGHT T, THOMAS DL, SEEFF LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
29. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002;36:s3-s20.
30. PUOTI M, ZONARO A, RAVAGGI A, MARIN MG, CASTELNUOVO F, CARIANI E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology 1992;16:877-881.
31. PAWLOTSKY JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36(Suppl 1):S65-S73.
32. RICE P. Screening and lab diagnosis of HCV. Acta Neuropsychiatrica 2006 [In press].
33. ALBERTI A, CHUMECK N, COLLINS S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-624.
34. TERJUNG B, LEMNITZER I, DUMOULIN FL et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003;67:138-145.
35. REGEV A, BERHO M, JEFFERS LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-2618.
36. THE FRENCH METAVIR COOPERATIVE STUDY GROUP. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
37. AFDHAL NH, NUNES D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99:1160-1174.
38. JOSEPH AE, SAVERYUTTU SH, AL-SAM S, COOK MG, MAXWELL JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26-31.
39. CASTERA L, VERGNIOL J, FOUCHER J et al. Prospective comparison of transient elastography, FibroTest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
40. LIM AKP, TAYLOR-ROBINSON SD, PATEL N et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005;54:128-133.
41. ROBAEYS G, BUNTINX F, BOTTIEAU E et al. Guidelines for the management of chronic hepatitis C in patients infected after substance abuse. Acta Gatroenterol Belg 2005;68:38-45.
42. HERRINE SK, FRIEDMAN LS. Divining the role of liver biopsy in hepatitis C. J Hepatol 2005;43:374-376.
43. GREEN ST, MOHSEN AH, MCKENDRICK MW et al. Potential for hepatitis C transmission among non-needle/syringe sharing Sheffield drug injectors through the sharing of drug preparation paraphernalia. Commun Dis Public Health 2001;4:38-41.
44. EDLIN BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;36(Suppl 1):S210-S219.
45. GOTZ HM, VAN DOORNUM G, NIESTERS HG, DEN HOLLANDER JG, THIO HB, DE ZWART O. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS 2005;19:969-974.
46. AKAHANE Y, KOJIMA M, SUGAI Y et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994;51:338-343.
47. OHTO H, TERAZAWA S, SASAKI N et al. Transmission of hepatitis C virus from mothers to infants. N Eng J Med 1994;330:744-750.
48. GIOVANNI M, TAGGER A, RIBERO ML et al. Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet 1990;335:1166.
49. RESTI M, AZARRI C, GALLI L et al. Maternal drug use is a pre-eminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicentre study of 1372 mother-infant pairs. J Infect Dis 2002;185:567-572.
50. OGASAWARA S, KAGE M, KOSAI K-I et al. Hepatitis C virus RNA in saliva and breastmilk of hepatitis C carrier mothers. Lancet 1993;341:561.
51. VENTO S, GAROFANO T, REZINI C et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Eng J Med 1998;338:286-290.
52. TSAI JF, JENG JE, HO MS, CHANG WY, LIN ZY, TSAI JH. Independent and additive effect modification of hepatitis B and C virus infection on the development of chronic hepatitis. J Hepatol 1996;24:271-276.
53. UK HEALTH DEPARTMENTS. Immunisation against infectious disease. London: HMSO, 1996.
54. MCGREGOR J, MARKS PJ, HAYWARD A, BELL Y, SLACK RCB. Factors influencing hepatitis B vaccine uptake in injecting drug users. J Public Health Med 2003;25:165-170.
55. WILEY TE, MCCARTHY M, BREIDE L, MCCARTHY M, LAYDEN JT. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809.
56. PESSIONE F, DEGOS F, MARCELLIN P et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-1722.
57. POWELL EE, JOHNSON JR, CLOUSTON AD. Steatosis: co-factor in other liver diseases. Hepatology 2005;42:5-13.
58. BRESSLER BL, GUINDI M, TOMLINSON G, HEATHCOTE J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-644.
59. SEEF LB, MILLER RN, RABKIN CS et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-111.
60. MARCELLIN P, BOYER N, GERVAIS A et al. Long-term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875-881.
61. HOOFNAGLE JH, MULLEN KD, JONES DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Eng J Med 1986;315:1575-1578.
62. POYNARD T, MARCELLIN P, LEE SS et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
63. FRIED MW, SHIFFMAN ML, REDDY KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002;347:975-982.
64. MANNS MP, MCHUTCHINSON JG, GORDON SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of hepatitis C: a randomised trial. Lancet 2001;358:958-965.
65. HADZIYANNIS SJ, SETTE H, MORGAN TR et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004;130:346-355.
66. HASAN F, ASKER H, AL-KHALDI J et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-1737.
67. MUIR AJ, BORNSTEIN JD, KILLENBERG PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Eng J Med 2004;350:2265-2271.
68. BACKMUND M, MEYER K, VON ZIELONKA M, EICHENLAUB D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-193.
69. JOWETT SL, AGARWAL K, SMITH BC et al. Managing chronic hepatitis C acquired through intravenous drug use. Q J Med 2001;94:153-158.
70. MAUSS S, BERGER F, GOELZ J, JACOB B, SCHMUTZ G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-124.
71. EDLIN BR, SEAL KH, LORVICK J et al. Is it justifiable to withhold treatment for hepatitis C from illicit drug users? N Eng J Med 2001;345:211-214.
72. SHEERIN IG, GREEN FT, SELLMAN JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev 2004;23:261-272.
73. MILLER NH. Compliance with treatment regimes in chronic asymptomatic diseases. Am J Med 1997;102:43-49.
74. MCHUTCHINSON JG, MANNS M, PATEL K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
75. COURNOT M, GLIBERT A, CASTEL F et al. Management of hepatitis C in active drug users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004;28:533-539.
76. DE BIE J, ROBAEYS G, BUNTINX F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (ivdu): guidelines for clinical practice. Acta Gastroenterol Belg 2005;68:68-80.
77. GOLUB ET, LATKA M, HAGAN H et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004;81:278-290.
78. MEHTA SH, COX A, HOOVER DR et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-1483.
79. DAVIS GL, RODRIGUE JR. Treatment of chronic hepatitis C in active drug users. N Eng J Med 2001;345:215-217.
80. DALGARD O, BJORO K, HELLUM K et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002;8:45-49.
81. EVERSON GT. Management of cirrhosis due to chronic hepatitis C. J Hepatol 2005;42:S65-S74.
82. RYDER SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52(Suppl III):iii1-iii8.
83. BRUIX J, SHERMAN M, LLOVET JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430.
84. HEATHCOTE EJ, SHIFFMAN ML, COOKSLEY WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Eng J Med 2000;343:1673-1680.
85. EVERSON GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003;9:905-915.
86. CRIPPIN JS, MCCASHLAND T, TERRAULT N, SHEINER P, CHARLTON MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.
87. MACKIE J, GROVES K, HOYLE A et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001;7:418-427.
88. LEVENSON JL, OLBRISCH ME. Psychosocial evaluation of organ transplant candidates: a comparative survey of process, criteria, and outcomes in heart, liver, and kidney transplantation. Psychosomatics 1993;34:314-323.
89. WEINRIEH RM, BARNETT R, LYNCH KG, DEPIANO M, ATANDA A, OLTHOFF KM. A matched comparison study of medical and psychiatric complications and anaesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl 2004;10:97-106.
90. POYNARD T, REGIMBEAU C, MYERS RP et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002; 1; CD000369.
91. JAECKEL E, CORNBERG M, WEDEMEYER H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Eng J Med 2001;345:1452-1457.
92. VILLANO SA, VLAHOV D, NELSON KE et al. Persistence of viraemia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914.
93. GERLACH JT, DIEPOLDER HM, ZACHOVAL R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
94. JAUNCEY M, MICALLEF JM, GILMOUR S et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004;190:1270-1274.
95. BROERS B, HELBLING B, FRANCOIS A et al. Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323-328.
96. CLARKE SM, MULCAHY FM. What's new for injection drug users with HIV infection? Sex Transm Infect 2003;79:80-83.
97. BENHAMOU Y, BOCHET M, DI MARTINO V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-1058.
98. TORRIANI FJ, RODRIGUEZ-TORRES M, ROCKSTROH JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Eng J Med 2004;351:438-450.
99. CHUNG RT, ANDERSEN J, VOLBERDING P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Eng J Med 2004;351:451-459.